Difference between revisions of "Abiraterone (Zytiga)"
m (categories) |
m (categories) |
||
| Line 16: | Line 16: | ||
<references/> | <references/> | ||
| + | [[Category:Drug index]] | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
| + | [[Category:Antiandrogens]] | ||
[[Category:Androgen synthesis inhibitors]] | [[Category:Androgen synthesis inhibitors]] | ||
Revision as of 21:58, 7 October 2012
General information
Class/mechanism: Antiandrogen, androgen biosynthesis inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Abiraterone (Zytiga) package insert PDF pages 5-6[3]
- Abiraterone (Zytiga) patient drug information (UpToDate)[4]